Advertisement
U.S. markets closed

Galmed Pharmaceuticals Ltd. (GLMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.3626+0.0036 (+1.00%)
At close: 03:56PM EST
0.3900 +0.03 (+7.56%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close0.3590
Open0.3600
Bid0.3633 x 900
Ask0.3664 x 900
Day's Range0.3600 - 0.3645
52 Week Range0.2600 - 5.6300
Volume32,490
Avg. Volume122,225
Market Cap1.453M
Beta (5Y Monthly)0.87
PE Ratio (TTM)N/A
EPS (TTM)-3.0200
Earnings DateMar 27, 2024 - Apr 01, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GLMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Galmed Pharmaceuticals Ltd.
    Analyst Report: Gilead Sciences, Inc.Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
    Rating
    Fair Value
    Economic Moat
    12 days agoMorningstar
View more
  • InvestorPlace

    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

    It’s time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth watching this morning! Moving stocks this morning are collaboration agreements, merger plans, earnings, public share offerings and more. Let’s get into that news down below!InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biggest Pre-Market Stock Movers: 10 Top Gainers Tracon Pharmaceuticals (NASDAQ:TCON) stock is rocketing more than 54% with heavy trading after announcing a product dev

  • PR Newswire

    Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

    Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.

  • PR Newswire

    Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

    Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the allowance of a Japanese patent related to treatment of pulmonary and dermal fibrosis. A similar patent was already granted in Mexico. The approval of the patent in the US and the rest of the world is pending. With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramch